SG10201901977XA - Hydrochloride salt form for ezh2 inhibition - Google Patents

Hydrochloride salt form for ezh2 inhibition

Info

Publication number
SG10201901977XA
SG10201901977XA SG10201901977XA SG10201901977XA SG10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA
Authority
SG
Singapore
Prior art keywords
salt form
hydrochloride salt
ezh2 inhibition
methyl
ezh2
Prior art date
Application number
SG10201901977XA
Inventor
Kevin W Kuntz
Hyeong-Wook Choi
Steven Mathieu
Kristen Sanders
Arani Chanda
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Publication of SG10201901977XA publication Critical patent/SG10201901977XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5 - (ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3- carboxamide hydrochloride, and related compositions and methods. [Figure 3]
SG10201901977XA 2013-10-16 2014-10-15 Hydrochloride salt form for ezh2 inhibition SG10201901977XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361891786P 2013-10-16 2013-10-16

Publications (1)

Publication Number Publication Date
SG10201901977XA true SG10201901977XA (en) 2019-04-29

Family

ID=52828660

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201901977XA SG10201901977XA (en) 2013-10-16 2014-10-15 Hydrochloride salt form for ezh2 inhibition
SG11201602269QA SG11201602269QA (en) 2013-10-16 2014-10-15 Hydrochloride salt form for ezh2 inhibition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201602269QA SG11201602269QA (en) 2013-10-16 2014-10-15 Hydrochloride salt form for ezh2 inhibition

Country Status (24)

Country Link
US (3) US10040782B2 (en)
EP (2) EP4324525A2 (en)
JP (2) JP6608812B2 (en)
KR (1) KR102142177B1 (en)
CN (1) CN105829302B (en)
AU (2) AU2014337300B2 (en)
CA (1) CA2925889C (en)
CL (1) CL2016000866A1 (en)
DK (1) DK3057962T3 (en)
EA (1) EA038869B1 (en)
ES (1) ES2960953T3 (en)
FI (1) FI3057962T3 (en)
HU (1) HUE063984T2 (en)
IL (1) IL244787B (en)
LT (1) LT3057962T (en)
MA (1) MA38949A1 (en)
MX (1) MX2016004703A (en)
MY (1) MY179802A (en)
PE (1) PE20161273A1 (en)
PL (1) PL3057962T3 (en)
PT (1) PT3057962T (en)
SG (2) SG10201901977XA (en)
SI (1) SI3057962T1 (en)
WO (1) WO2015057859A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4190777A1 (en) 2012-04-13 2023-06-07 Epizyme, Inc. Hbr salt form for ezh2 inhibition
MY179802A (en) 2013-10-16 2020-11-16 Eisai R&D Man Co Ltd Hydrochloride salt form for ezh2 inhibition
EP3076977B1 (en) 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
PL3157527T3 (en) 2014-06-17 2023-08-07 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
AU2015331729A1 (en) 2014-10-16 2017-04-13 Epizyme, Inc. Method for treating cancer
MX2017006089A (en) * 2014-11-17 2017-12-11 Epizyme Inc Method for treating cancer.
US10456407B2 (en) 2015-04-20 2019-10-29 Epizyme, Inc. Combination therapy for treating cancer
WO2016201328A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (en) 2016-06-17 2019-04-24 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
TW201831181A (en) 2017-01-19 2018-09-01 日商第一三共股份有限公司 Therapeutic agent for htlv-1-associated myelopathy
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (en) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド Use of EZH2 inhibitors for treating cancer
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (en) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Production of n-cyano-n'-substituted-arylcarboxyimidamide compound
WO1995018097A1 (en) 1993-12-27 1995-07-06 Eisai Co., Ltd. Anthranilic acid derivative
DE19516776A1 (en) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin regulatory genes
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (en) 1995-12-18 2007-04-18 杏林製薬株式会社 N-substituted dioxothiazolidylbenzamide derivative and process for producing the same
AU6060099A (en) 1998-09-30 2000-04-17 Procter & Gamble Company, The 2-substituted ketoamides
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2433158C (en) 2000-12-28 2011-05-10 Shionogi & Co., Ltd. Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
JPWO2003070277A1 (en) 2002-02-19 2005-06-09 塩野義製薬株式会社 Antipruritic agent
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
JP5160885B2 (en) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Reconstituted histone methyltransferase complex and method for identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (en) 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
PL1940821T3 (en) 2005-10-19 2013-08-30 Gruenenthal Gmbh Novel vanilloid receptor ligands and their use for producing medicaments
ATE510822T1 (en) 2005-10-21 2011-06-15 Merck Sharp & Dohme POTASSIUM CHANNEL INHIBITORS
EP1941060B1 (en) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AU2006336552B2 (en) 2006-01-20 2012-12-20 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
CN101443007A (en) 2006-05-15 2009-05-27 Irm责任有限公司 TEREPHTHALAMATE compounds and compositions, and their use as HIV integrase inhibitors
EP2040711A2 (en) 2006-05-18 2009-04-01 Amphora Discovery Corporation 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents
WO2008108825A2 (en) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (en) 2007-04-13 2008-10-16 Grünethal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
JP2011502148A (en) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション P2X3 receptor antagonist for the treatment of pain
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2335779A1 (en) 2008-08-08 2011-06-22 New York Blood Center Small Molecule Inhibitors of Retroviral Assembly & Maturation
FR2934995B1 (en) 2008-08-14 2010-08-27 Sanofi Aventis POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
JP2012522013A (en) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション Regulated IRES-mediated translation
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
RU2013130253A (en) 2010-12-03 2015-01-10 Эпизайм, Инк. 7-DEAZAPURINE HISTONIC METHYL TRANSFERASES AND WAYS OF THEIR APPLICATION
JP2014511389A (en) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TWI598336B (en) 2011-04-13 2017-09-11 雅酶股份有限公司 Substituted benzene compounds
KR102587175B1 (en) 2012-03-12 2023-10-06 에피자임, 인코포레이티드 Inhibitors of human ezh2, and methods of use thereof
BR112014025506B1 (en) 2012-04-13 2024-02-06 Epizyme, Inc COMPOSITION COMPRISING EZH2 INHIBITOR COMPOUND, THERAPEUTIC USE THEREOF AND IN VITRO METHOD OF INHIBITING THE PROLIFERATION OF CANCER CELLS
EP4190777A1 (en) 2012-04-13 2023-06-07 Epizyme, Inc. Hbr salt form for ezh2 inhibition
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders
PL2908823T3 (en) 2012-10-15 2020-03-31 Epizyme, Inc. Methods of treating cancer
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc Substituted 6,5-fused bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
MY179802A (en) 2013-10-16 2020-11-16 Eisai R&D Man Co Ltd Hydrochloride salt form for ezh2 inhibition

Also Published As

Publication number Publication date
AU2019202246A1 (en) 2019-04-18
FI3057962T3 (en) 2023-11-03
JP2019052181A (en) 2019-04-04
CL2016000866A1 (en) 2016-12-23
IL244787B (en) 2022-04-01
DK3057962T3 (en) 2023-11-06
EA201690650A1 (en) 2016-10-31
IL244787A0 (en) 2016-04-21
MA38949A1 (en) 2017-07-31
JP2016533349A (en) 2016-10-27
PE20161273A1 (en) 2016-12-18
AU2014337300B2 (en) 2019-01-03
CN105829302B (en) 2020-09-08
CA2925889A1 (en) 2015-04-23
PL3057962T3 (en) 2024-01-29
AU2014337300A1 (en) 2016-04-14
ES2960953T3 (en) 2024-03-07
KR20160082993A (en) 2016-07-11
PT3057962T (en) 2023-11-07
EP3057962B1 (en) 2023-10-18
SI3057962T1 (en) 2024-01-31
US10040782B2 (en) 2018-08-07
US20180282312A1 (en) 2018-10-04
LT3057962T (en) 2023-12-11
KR102142177B1 (en) 2020-08-07
EP4324525A2 (en) 2024-02-21
MY179802A (en) 2020-11-16
EA038869B1 (en) 2021-10-29
JP6608812B2 (en) 2019-11-20
US20160237068A1 (en) 2016-08-18
MX2016004703A (en) 2017-02-28
NZ718201A (en) 2021-09-24
EP3057962A4 (en) 2017-05-24
HUE063984T2 (en) 2024-02-28
US20210017163A1 (en) 2021-01-21
WO2015057859A1 (en) 2015-04-23
SG11201602269QA (en) 2016-04-28
CA2925889C (en) 2020-09-29
US10710987B2 (en) 2020-07-14
CN105829302A (en) 2016-08-03
EP3057962A1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
SG10201901977XA (en) Hydrochloride salt form for ezh2 inhibition
MX362339B (en) Salt form of a human hi stone methyltransf erase ezh2 inhibitor.
DK3220916T3 (en) METHOD FOR TREATMENT OF CANCER WITH N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL)AMINO) -4-METHYL-4'-(MORPHOLINOMETHYL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE
EA201991884A2 (en) G12C KRAS INHIBITORS
EA201690752A1 (en) INHIBITORS G12C KRAS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
PH12018500777A1 (en) Farnesoid x receptor modulators
PH12015500719A1 (en) Gdf-8-inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2019009501A (en) Amino pyrimidine compounds useful as ssao inhibitors.
JO3452B1 (en) Aminoheteroaryl benzamides as kinase inhibitors
EA201590748A1 (en) ANTI-VIRUS CONNECTIONS AGAINST RSV
GEP201706699B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MX2015012850A (en) Arginine methyltransferase inhibitors and uses thereof.
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
EA201490471A1 (en) PYRIDAZINOUS COMPOUNDS AND THEIR APPLICATION AS DAAO INHIBITORS
EA029499B9 (en) Rorc2 inhibitors and methods of use thereof
IL273974B1 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
EA201391299A1 (en) PEPTIDDEFORMILASE INHIBITORS
IN2013MU03565A (en)